This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Relugolix

Myovant Sciences Ltd.

Drug Names(s): TAK-385

Description: Relugolix is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist.

Deal Structure: Roivant and Takeda
In June 2016, Takeda and Roivant announced the formation of Myovant Sciences Ltd., a biopharmaceutical company focused on delivering womens health and prostate cancer solutions by advancing new medicines to market. Takeda has granted Myovant an exclusive, worldwide license (excluding Japan and certain other Asian countries) to relugolix (TAK-385). Relugolix is being developed as an oral, once-daily, potential best-in-class gonadotropin-releasing hormone (GnRH) receptor antagonist for uterine fibroids, endometriosis and prostate cancer. Takeda will retain commercial rights for relugolix in Asian countries, including Japan, where Takeda is actively conducting two Phase III registration studies for the treatment of uterine fibroids. Takeda has also granted Myovant an exclusive, worldwide license to RVT-602 (TAK-448), a novel, oligopeptide kisspeptin receptor agonist as a product candidate for the treatment of infertility in females. Financial terms of the...See full deal structure in Biomedtracker

Partners: Takeda Pharmaceutical Company Ltd Roivant Sciences Ltd


Relugolix News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug